Side-by-side comparison of AI visibility scores, market position, and capabilities
British consumer health company with £14B revenue; Lysol, Mucinex, Nurofen, and Durex brands managing Mead Johnson infant formula litigation while competing with P&G and J&J.
Reckitt is a British multinational consumer health and hygiene company producing market-leading brands including Nurofen (ibuprofen), Strepsils, Dettol, Lysol, Durex, Mucinex, Enfamil infant formula, and Woolite — competing across OTC health, hygiene and home, and nutrition categories. Listed on the London Stock Exchange (LSE: RKT) and headquartered in Slough, England, Reckitt generates approximately £14 billion ($17 billion) in annual revenue. The company has undergone significant portfolio reshaping, divesting its Infant Formula & Child Nutrition (IFCN) business in some markets and selling Mead Johnson Nutrition operations.\n\nReckitt's business is organized into two segments: Health (Nurofen, Strepsils, Gaviscon, Mucinex, DayQuil/NyQuil in North America) and Hygiene and Home (Lysol/Dettol disinfectants, Finish dishwasher tablets, Vanish stain remover, Air Wick). The Health segment benefits from strong brand equity in OTC medications that command premium pricing. The Hygiene segment's Lysol brand benefited significantly from COVID-19 disinfectant demand and has sustained elevated brand awareness post-pandemic.\n\nIn 2025, Reckitt faces ongoing challenges from its $2.4 billion acquisition of Mead Johnson (Enfamil) — the company has faced significant litigation related to NEC (necrotizing enterocolitis) lawsuits claiming preterm infant formula contributed to infant deaths, resulting in large court judgments against Reckitt in 2024. The company is managing these legal liabilities while continuing to run its core consumer health and hygiene portfolio. Reckitt competes with Procter & Gamble, Johnson & Johnson, and Haleon for OTC health and hygiene market share. The 2025 strategy focuses on its Power Brands in health and hygiene, cost efficiency, and resolving the Mead Johnson litigation exposure.
SF YC W24 AI support agent builder at 80% resolution time reduction and 71% ticket deflection; $500K from a16z/Greylock/YC/Netflix competing with Intercom Fin for customer support AI workflow automation.
Duckie is a San Francisco-based AI customer support platform — backed by Y Combinator (W24) with $500,000 in funding from Y Combinator, Andreessen Horowitz, Greylock, KungHo Fund, Netflix, and 5 additional investors — providing customer support teams with an AI agent builder that translates existing support processes and workflows into predictable, reliable AI automation, achieving 80% reduction in resolution time and 71% ticket deflection for deployed teams. Founded in 2023 and targeting customer support leaders at growth-stage software companies, Duckie enables support teams to deploy AI agents in minutes without engineering dependency.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.